REGENXBIO, Inc.

As of August 25, 2025, REGENXBIO, Inc. shows a mildly bullish technical trend, supported by bullish daily moving averages and a weekly MACD, despite mixed indicators on longer timeframes and a year-to-date return of 21.09% compared to the S&P 500's 12.22%.

As of February 28, 2023, REGENXBIO, Inc. is considered overvalued with a risky financial outlook, reflected by poor return metrics and significant underperformance compared to the S&P 500.

As of February 28, 2023, REGENXBIO, Inc. is considered overvalued and risky due to negative earnings metrics and poor performance compared to peers, with a 1-year return of -34.61% versus the S&P 500's 10.26%.

As of June 20, 2025, the technical trend is mildly bearish, indicated by bearish daily moving averages and Bollinger Bands, despite some bullish signals from the MACD.

As of March 2022, the management team of REGENXBIO, Inc. includes Chairman Allan Fox, CEO Kenneth Mills, Lead Independent Director A. N. Karabelas, and independent directors Daniel Abdun-Nabi, Luke Beshar, Alexandra Glucksmann, and David Stump. This team provides governance and strategic direction for the company.

REGENXBIO, Inc. is a clinical-stage biotechnology company focused on gene therapy to address genetic defects. As of March 2025, it reported net sales of $89 million and a market cap of $436.37 million.

As of Jun 18, REGENXBIO, Inc. has a market capitalization of 436.37 million, with net sales of 156.72 million and a net profit of -157.70 million over the latest four quarters. The company reported shareholder's funds of 259.65 million and total assets of 465.99 million as of Dec 24.